These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
210 related items for PubMed ID: 8322271
1. Effects of hybrid peptide analogs to receptor recognition domains on alpha- and gamma-chains of human fibrinogen on fibrinogen binding to platelets. Mohri H, Ohkubo T. Thromb Haemost; 1993 May 03; 69(5):490-5. PubMed ID: 8322271 [Abstract] [Full Text] [Related]
3. "Bridged" peptide of fibrinogen binds to platelets activated by RGD peptide as well as by ADP. Mohri H, Ohkubo T. Peptides; 1994 May 03; 15(4):683-7. PubMed ID: 7937346 [Abstract] [Full Text] [Related]
4. Inhibition of von Willebrand factor binding to platelets by two recognition site peptides: the pentadecapeptide of the carboxy terminus of the fibrinogen gamma chain and the tetrapeptide arg-gly-asp-ser. Williams S, Gralnick H. Thromb Res; 1987 May 01; 46(3):457-71. PubMed ID: 3037722 [Abstract] [Full Text] [Related]
6. The role of the RGD peptides and the gamma chain peptide of fibrinogen on fibrinogen binding to activated platelets. Mohri H, Ohkubo T. Peptides; 1993 May 01; 14(2):353-7. PubMed ID: 8483813 [Abstract] [Full Text] [Related]
8. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist. Huang TF, Liu CZ, Ouyang CH, Teng CM. Biochem Pharmacol; 1991 Aug 22; 42(6):1209-19. PubMed ID: 1888330 [Abstract] [Full Text] [Related]
9. Antiplatelet "hybrid" peptides analogous to receptor recognition domains on gamma and alpha chains of human fibrinogen. Timmons S, Bednarek MA, Kloczewiak M, Hawiger J. Biochemistry; 1989 Apr 04; 28(7):2919-23. PubMed ID: 2742820 [Abstract] [Full Text] [Related]
10. Glycoprotein IIb peptide 656-667 mimics the fibrinogen gamma chain 402-411 binding site on platelet integrin GPIIb/IIIa. Calvete JJ, Rivas G, Schäfer W, McLane MA, Niewiarowski S. FEBS Lett; 1993 Nov 29; 335(1):132-5. PubMed ID: 8243658 [Abstract] [Full Text] [Related]
11. Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets. Ruggeri ZM, Houghten RA, Russell SR, Zimmerman TS. Proc Natl Acad Sci U S A; 1986 Aug 29; 83(15):5708-12. PubMed ID: 3016716 [Abstract] [Full Text] [Related]
14. The Arg-Gly-Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on nonactivated platelets is accessible to high-affinity macromolecules. Tomiyama Y, Tsubakio T, Piotrowicz RS, Kurata Y, Loftus JC, Kunicki TJ. Blood; 1992 May 01; 79(9):2303-12. PubMed ID: 1373972 [Abstract] [Full Text] [Related]
15. Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749). Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, King LW, Miyano M, Gorczynski RJ, Williams MH, Zupec ME, Tjoeng FS. J Pharmacol Exp Ther; 1991 Mar 01; 256(3):876-82. PubMed ID: 2005585 [Abstract] [Full Text] [Related]
17. A discrete sequence in a platelet integrin is involved in ligand recognition. D'Souza SE, Ginsberg MH, Matsueda GR, Plow EF. Nature; 1991 Mar 07; 350(6313):66-8. PubMed ID: 2002847 [Abstract] [Full Text] [Related]
18. Fibronectin inhibits platelet aggregation independently of RGD sequence. Tanabe J, Fujita H, Iwamatsu A, Mohri H, Ohkubo T. J Biol Chem; 1993 Dec 25; 268(36):27143-7. PubMed ID: 8262952 [Abstract] [Full Text] [Related]